2 Reasons Why Allergan Stock Plunged in 2017
Allergan's shares fell off a cliff last year. Can it rebound in 2018?
What to expect at CES 2018, the biggest gadget show of the year
Everything you can expect from the biggest tech show of the year.
In A Year When Bitcoin Stole The Spotlight, Energy Was An Underappreciated Winner
The year 2017 was a strong one in financial markets, as assets across categories made handsome gains. The standout performer, though, was an asset that's been treated with some skepticism among the investing ...
10 Soft Skills Hiring Managers Are Looking For
Want to land a great job or excel at your current one? Here are some key interpersonal skills to focus on.
Celgene readies deal to buy Impact Biomedicines for as much as $7 billion – WSJ
Celgene Corp is expected to announce Monday that it is acquiring Impact Biomedicines for as much as $7 billion (£5.1 billion), the Wall Street Journal reported Sunday. Subsequent components of the deal would depend on approval from the Food and Drug Administration and successful acceptance in the market, according to the publication. Celgene and Impact Biomedicines did not immediately respond to requests for comment.
Steve Bannon Apologizes For Controversial Comments About Donald Trump Jr.
"Donald Trump Jr. is both a patriot and a good man."
Retired? You're Probably Ignoring Your Biggest Risk Factor
Sequence-of-returns risk is a significant but often ignored issue for retirees.